A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Public ClinicalTrials.gov record NCT01887886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab in Combination With Erlotinib as First-Line Treatment for Patients With MET-Positive Unresectable Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation
Study identification
- NCT ID
- NCT01887886
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- erlotinib Drug
- onartuzumab Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Jan 31, 2015
- Completion
- Jan 31, 2015
- Last update posted
- Nov 1, 2016
2013 – 2015
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Fullerton | California | 92835 | — |
| Not listed | Long Beach | California | 90813 | — |
| Not listed | Los Angeles | California | 90095-1772 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | San Luis Obispo | California | 93454 | — |
| Not listed | Fort Myers | Florida | 33905 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | St. Petersburg | Florida | 33705 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Marrero | Louisiana | 70072 | — |
| Not listed | Metairie | Louisiana | 70006 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Canton | Ohio | 44718 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01887886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced May 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01887886 live on ClinicalTrials.gov.